Add to ORKGA 48-year-old Thai female, who had stage 2 carcinoma of the breast presented with recalcitrant erythrodermic psoriasis which was unresponsive to conventional therapies. She was prescribed 6 mg/kg · day cyclosporinA. The erythroderma responded rapidly and was completely cleared within 3 weeks. The dosage was reduced in a step-wise manner to 4 and then 2 mg/kg · day and was stopped after 2 months of treatment. Complete clearing of the skin lesion was observed without any side-effectsexcept mild nausea. The patient was then referred to surgery for mastectomy and chemotherapy. There was no clinical relapse during more than 1 year of follow-up and at present she is continuing to do well. KEY WORDS: Recalcitrant erythrodermic psoriasis; cyclospor...
OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of long-term treatmen...
We set out to show that the assumption is incorrect that continuous treatment with cyclosporin is ne...
Background: Although long-term cyclosporine administration may induce toxic effects, it may be the o...
Cyclosporine A, a unique immunomodulatory agent, has been used increasingly over the last 5 years in...
Introduction . It is estimated that erythroderma affects about 1–2% of patients with psoriasis. O...
Cyclosporin A (CYA) has recently attracted the attention of the dermatologists with regard to its us...
textabstractAlthough a large therapeutic arsenal of conventional drugs is available to treat patient...
Introduction: Cyclosporine (CsA) is a calcineurin inhibitor immunosuppressive. Although highly effec...
Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cel...
We described in this case report a 62 years-old women with a history of modified radical mastectomy ...
Abstract Background Thymectomy can effectively cure most thymoma patients; however, patients with ad...
Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized...
Cyclosporine A belongs to calcineurin inhibitor family, which has the ability to selectively suppres...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Efalizumab is a recombinant humanized anti-CD11a monoclonal antibody that blocks the activation, adh...
OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of long-term treatmen...
We set out to show that the assumption is incorrect that continuous treatment with cyclosporin is ne...
Background: Although long-term cyclosporine administration may induce toxic effects, it may be the o...
Cyclosporine A, a unique immunomodulatory agent, has been used increasingly over the last 5 years in...
Introduction . It is estimated that erythroderma affects about 1–2% of patients with psoriasis. O...
Cyclosporin A (CYA) has recently attracted the attention of the dermatologists with regard to its us...
textabstractAlthough a large therapeutic arsenal of conventional drugs is available to treat patient...
Introduction: Cyclosporine (CsA) is a calcineurin inhibitor immunosuppressive. Although highly effec...
Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cel...
We described in this case report a 62 years-old women with a history of modified radical mastectomy ...
Abstract Background Thymectomy can effectively cure most thymoma patients; however, patients with ad...
Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized...
Cyclosporine A belongs to calcineurin inhibitor family, which has the ability to selectively suppres...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Efalizumab is a recombinant humanized anti-CD11a monoclonal antibody that blocks the activation, adh...
OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of long-term treatmen...
We set out to show that the assumption is incorrect that continuous treatment with cyclosporin is ne...
Background: Although long-term cyclosporine administration may induce toxic effects, it may be the o...